Skip to main content

Table 2 Hazard ratios of breast cancer disease-free survival for several basic characteristics by breast cancer subtyping

From: Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival

    Molecular subtyping
  All        Five subtypes Four subtypes
Variables (N = 951) IHC-Luminal A
(N = 486)
IHC-Luminal B
(N = 123)
IHC-HER2
(N = 113)
IHC-BLBC
(N = 139)
IHC-QNBC/5NP
(N = 90)
IHC-TNBC
(N = 229)
  HR(N of event) HR(N of event) HR(N of event) HR(N of event) HR(N of event) HR(N of event) HR(N of event)
  (95%CI) p-value (95%CI) p-value (95%CI) p-value (95%CI) p-value (95%CI) p-value (95%CI) p-value (95%CI) p-value
Age Group (yr)               
   > 50 1.00(174/590)   1.00(79/297)   1.00(32/87)   1.00(25/51)   1.00(22/97)   1.00(16/58)   1.00(38/155)  
   ≥ 50 0.73(82/361)   0.72(38/189)   0.88(12/36)   0.42(16/62)   0.70(7/42)   1.07(10/32)   0.89(17/74)  
  (0.55-0.96) 0.020 (0.49-1.07) 0.856 (0.45-1.71) 1.0 (0.21-0.79) 0.056 (0.29-1.60) 1.0 (0.48-2.37) 1.0 (0.50-1.58) 1.0
Tumor size (cm)               
   ≤ 2 cm 1.00(77/392) 1.00(38/228)   1.00(16/39)   1.00(8/35)   1.00(9/52)   1.00(6/38)   1.00(15/90)  
   2-5 cm 1.62(146/493) 1.86(23/75)   0.73(23/75)   1.93(25/64)   1.04(14/76)   2.72(17/47)   1.59(31/123)  
  (1.23-2.14) 0.001 (1.25-2.77) 0.016 (0.38-1.38) 1.0 (0.87-4.27) 0.864 (0.45-2.39) 1.0 (1.07-6.89) 0.288 (0.86-2.94) 1.0
   > 5cm 3.14(33/66)   3.32(12/27)   1.34(5/9)   2.65(7/14)   4.04(6/11)   4.67(3/5)   4.30(8/16)  
  (2.08-4.72) < 0.001 (.1.73-6.35) < 0.001 (0.49-3.67) 1.0 (0.96-7.30) 0.480 (1.43-11.22) 0.064 (1.16-18.22) 0.240 (1.90-9.82) 0.008
LN involvement               
   Negative 1.00(85/503) 1.00(31/248)   1.00(15/53)   1.00(18/64)   1.00(12/89)   1.00(9/49)   1.00(21/138)  
   Positive 2.54(171/448) 3.28(86/238)   1.60(29/70)   1.88(22/49)   2.75(17/50)   2.83(17/41)   2.83(34/91)  
  (1.96-3.30) < 0.001 (2.17-4.95) 0.001 (0.86-2.98) 0.980 (1.01-3.51) 0.376 (1.32-5.77) 0.045 (1.26-6.36) 0.096 (1.64-4.89) < 0.001
AJCC stage               
   I 1.00(36/254) 1.00(14/148)   1.00(8/19)   1.00(4/22)   1.00(5/38)   1.00(5/27)   1.00(10/65)  
   II 1.62(106/467) 2.62(50/221)   0.55(18/69)   2.02(19/57)   1.24(13/78)   0.79(6/42)   1.03(19/120)  
  (1.02-2.14) 0.001 (1.45-4.74) 0.008 (0.24-1.26) 1.0 (0.68-5.94) 1.0 (0.44-3.48) 1.0 (0.24-3.48) 1.0 (0.48-2.20) 1.0
   III 3.14(114/230)   5.86(53/117)   1.32(18/35)   3.59(17/34)   4.31(11/23)   6.30(15/21)   5.14(26/44)  
  (2.08-4.72) < 0.001 (3.24-10.55) 0.001 (0.58-3.04) 1.0 (1.21-10.67) 0.176 (1.49-12.41) 0.056 (2.27-17.5) 0.001 (2.47-10.66) < 0.001
Adjuvant chemotherapy               
   Not done 1.00(43/155) 1.00(17/95)   1.00(9/20)   1.00(10/22)   1.00(6/10)   1.00(1/8)   1.00(7/18)  
   Done 0.98(213/796) 1.57(100/391)   0.63(35/103)   0.69(30/91)   0.24(23/129)   3.13(25/82)   0.59(48/211)  
  (0.71-1.36) 0.915 (0.94-2.64) 0.083 (0.31-1.32) 0.226 (0.34-1.42) 0.312 (0.10-0.60) 0.002 (0.43-23.2) 0.26 (0.26-1.30) 1.0
  1. IHC: immunohistochemistry, LN: lymph node